INNOVIVA, INC. (INVA): what the price assumes

boothcheck covers INNOVIVA, INC. (INVA) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed 2026-06-27.

Generated: 2026-07-29 · Exported: 2026-08-01 · Source: https://boothcheck.com/report/INVA

Headline

FieldValue
TickerINVA
CompanyINNOVIVA, INC.
Current price$21.70/sh
CompositionRoyalty revenue, net 57% / Net product sales 42% / License and other revenue 1%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin (value-band context)19.4%
Operating margin (mid-cycle)85.6%
Margin compression (value-band)-66.2pp
Trailing margin (depressed year)38.1%
Multiple paid5x mid-cycle operating income

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

The price sits below what even a 5%/yr operating-profit decline would warrant; the inversion reports a bound, not a solved growth path.

Solve inputs: computed at a 7% cost of capital with 4% terminal growth over a 5-year stage (computed at the 7% minimum rate; the CAPM rate 6.1% sits below it).

How unusual the bet is: within-range

ReferenceValue
vs own history-1.03σ
cohort percentile (of 116 peers)0
implied end-window share0%

Valuation X-Ray

The price is supported by asset-based and earnings-power and relative-multiple and growth-DCF value. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset0.29x5justifies
Earnings0.70x5justifies
Relative0.29x5justifies
Growth0.90x3justifies

Families that justify the price: Asset, Earnings, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.2%); the inversion above states its own rate.

Per-Model Detail (n=18)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$54.790.40xyesFCF base $0.2B, growth 14% (input: historical growth), terminal g 4.0%, WACC 8.1%, 6yr projection
DCF Exit MultipleGrowth$24.040.90xyesExit EV/EBITDA: 5.9x / 7.9x / 9.9x (bear / base = today's held flat / bull), 6yr
Relative ValuationRelative$77.160.28xyesP/E 15.67x (blended: static sector reference 24x + trailing (TTM) 3x), scenarios: 13.0x / 15.7x / 18.4x (bear / base = reference held flat / bull), EV/EBITDA 12.76x
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$73.870.29xyesBV/sh $18.18, ROE (TTM) 37.6%, ke 9.3%
Two-Stage Excess ReturnAsset$162.270.13xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$12.911.68xyesRev $0.4B, growth 14% (input: historical growth; tapered), Terminal P/S: 3.1x / 3.8x / 4.5x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$75.120.29xyesEPS $6.26, growth 2% (input: historical EPS growth), PEG=1.59 (Overvalued)
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings$16.221.34xyesNormalized EBIT (5y avg op income, one-time charges added back) $0.16B × (1−20%) / WACC 8.1% → EPV (no growth)
Residual IncomeAsset$116.130.19xyesBV $18.18 + 5yr PV of (ROE (TTM) 37.6% − Kₑ 9.3%) × BV; BV grows 8.8%/yr
Graham NumberAsset$50.600.43xyes√(22.5 × EPS $6.26 × BVPS $18.18) — Graham's conservative floor
EV/EBITDA RelativeRelative$39.310.55xyesEBITDA $0.16B × sector EV/EBITDA 16.0x
FCF YieldEarnings$31.170.70xyesFCF $182.0M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF YieldEarnings$29.730.73xyesSBC-adj FCF $0.17B (FCF $0.18B − SBC $0.01B) capitalized at Kₑ
Ben Graham FormulaEarnings$201.990.11xyesEPS $6.26 × (8.5 + 2×15.0%) × (4.4 / 5.3%)
ROIC-Justified P/BAsset$6.723.23xyesBV $18.18 × (ROIC 3.0% / WACC 8.1%)
P/Sales SectorRelative$22.800.95xyesRevenue $0.42B × sector P/S 4.0x
PEG Fair ValueRelative$234.750.09xyesEPS $6.26 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x
Earnings YieldEarnings$67.680.32xyesEPS $6.26 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net cash$345.0m
Net debt / NOPAT (after-tax)-1.20x (net cash)
Net debt / operating income (pre-tax)-0.96x (net cash)
Interest coverage20.7x
Share count CAGR (buyback)-2.5%
Burning cashno

Leverage and coverage are computed on normalized mid-cycle operating income (mid-cycle margin 85.6%); the trailing year was depressed.

Bullet Takeaways

Bull Case

Pharmaceutical royalty companies are a strange and underappreciated corner of the market, because they invert the usual drug-company risk. A traditional pharma spends years and billions to discover a drug, then prays it clears trials and sells. A royalty holder skips the discovery risk and collects a percentage of someone else's sales. Innoviva's core is a slice of GSK's respiratory franchise, which means it earns money on inhalers prescribed for asthma and COPD without running a single clinical trial or sales force for them. The 10-K is direct that a portion of revenue "are from royalties derived from sales of our respiratory products partnered with GSK, RELVAR/BREO ELLIPTA and ANORO ELLIPTA". That is high-margin, low-effort cash, and it is why the company runs a 38% operating margin.

The company has been using that cash to build a second engine, and it is growing fast. Net product sales, the hospital-focused drugs Innoviva markets directly, reached $41.4 million in the most recent quarter, up 37% year over year, led by GIAPREZA, XACDURO, and XERAVA. For the full prior year, product sales grew 77%. This is the pivot: from passively collecting respiratory royalties to actively building an infectious-disease and critical-care commercial business. The royalty stream funds the buildout, so the growth is self-financed rather than dilutive.

The valuation is the unusual part. This is not a company where you have to squint and assume a heroic future to justify the price. Every family of valuation method, asset value, earnings power, peer multiples, and forward growth, supports the current price. It is a value and asset-supported name, not a pure growth bet. Backing that up is a clean balance sheet: net cash of roughly $345 million, interest coverage above 20 times, and a share count that has actually fallen about 2.5% a year as the company buys back stock. A profitable, cash-generative business trading where the conservative methods already endorse it is a different animal from the typical small-cap story stock.

Bear Case

The moat here is eroding by design, and that is the bear case. A royalty on someone else's drug is the opposite of a durable franchise: it is a wasting asset. The respiratory royalties that anchor Innoviva run on GSK's inhalers, and the 10-K is candid that RELVAR/BREO ELLIPTA and ANORO ELLIPTA "face substantial competition for their intended uses in the targeted markets from products discovered, developed, launched and commercialized both by GSK and by other pharmaceutical companies, which could cause the royalties payable to us" to decline. GSK royalty revenue already slipped in the most recent quarter, to $58.6 million from $61.3 million a year earlier, and full-year royalties have been drifting down. The clock on every royalty stream eventually runs out as patents expire and competitors arrive. The bear question is whether the new product business grows faster than the old royalty business fades.

That hands the thesis to a hospital-drug portfolio that is small and concentrated. The product sales are led by a handful of critical-care and anti-infective drugs, which means the second engine depends on a few products winning formulary access and holding pricing in a tough hospital market. Anti-infectives in particular are a difficult commercial category, often used sparingly to preserve effectiveness, which caps volume. The 37% growth is real, but it is growth off a small base against drugs that have not yet proven they can scale into a franchise that replaces the royalty cash dollar for dollar.

The offsetting comfort is that this is not a balance-sheet bear. Innoviva carries net cash, covers its interest many times over, and is buying back stock rather than diluting. The risk is not insolvency; it is that the company becomes a melting ice cube where the royalty decline outpaces the product ramp, and a value-supported price slowly de-rates as the high-margin royalty mix gives way to a lower-margin, harder-to-win commercial business. The capital allocation has also drawn scrutiny over the years for equity-stake investments outside the core, which adds a layer of complexity to what should be a simple cash-collection story.

Valuation

What sets Innoviva apart from most names is that the price does not demand a leap of faith. The methods agree. Asset value, earnings power, peer multiples, and forward growth all support the current price, which the framework characterizes as a value and asset-supported name rather than a pure growth bet. When every family endorses the price, there is no large premium to explain; the question shifts from is it too expensive to is the underlying cash durable.

That durability is the real valuation debate, and it sits in the mix between a declining royalty stream and a rising product business. The royalty revenue is the higher-margin half, and it is slowly shrinking; the product sales are the faster-growing half, and they carry the costs of a real commercial operation. The blended operating margin of roughly 38% reflects today's mix. As product sales become a larger share, that blend will look more like a specialty-pharma margin and less like a pure royalty margin, which is the slow re-rating risk a holder underwrites. The company sits among drug-manufacturer peers, but its royalty core makes it an unusual member of that cohort.

The balance sheet removes the downside tail. Net cash of about $345 million, interest coverage north of 20 times, and a share count falling about 2.5% a year mean there is no leverage risk and active capital return. Solvency is not the concern. The decisive variable is whether the product portfolio compounds fast enough to offset the royalty fade, because the price today is fair on the current cash; it stays fair only if that cash holds its shape.

Catalysts

The most recent quarter, the first of 2026, framed the two-track story cleanly. Total revenue rose 11% year over year to $98.0 million, with GSK royalty revenue of $58.6 million down slightly from $61.3 million a year earlier, and net product sales of $41.4 million up 37%, split between $34.2 million in the U.S. and $7.2 million internationally. The U.S. product strength came from GIAPREZA at $19.7 million, XACDURO at $11.6 million, and XERAVA at $2.5 million, the trio that defines the commercial pivot.

The larger capital event was the monetization of the TRELEGY royalty, for which the company received a substantial upfront payment. Converting a future royalty stream into cash today is a deliberate choice: it pulls forward value from a wasting asset and gives the company dry powder for the product business and for buybacks, at the cost of giving up the later years of that particular royalty. Whether that trade looks smart depends on what the cash is redeployed into.

The forward signal to track is the same divergence the quarter showed: product sales growth against royalty decline. Each subsequent print is a referendum on whether the hospital-drug portfolio is scaling fast enough to carry the company as the GSK respiratory royalties continue their slow drift down.

Peer Cohorts (Per Segment, With Filing Citations)

Innoviva (single segment) (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Innoviva Q1 2026 earnings release · Innoviva 8-K, 2026

View the full interactive INVA report on boothcheck